Incidence of Metastasis in the Central Nervous System in Advanced Breast Cancer Treated With CDK 4/6 Inhibitors: A Multicenter, Retrospective Study
Abstract Central nervous system (CNS) metastasis remains a major cause of mortality in advanced breast cancer (ABC). While cyclin‐dependent kinase 4/6 inhibitors (CDKIs) combined with endocrine therapy (ET) delay resistance in hormone receptor (HR)‐positive and human epidermal growth factor receptor...
Saved in:
| Main Authors: | Yan‐Ling Wen, Xi‐Wen Bi, Xue‐Wen Zhang, Si‐Fen Wang, Chang Jiang, Li Wang, Yong‐Yi Zhong, Yuan‐Yuan Huang, Jian‐Li Zhao, Qian‐Jun Chen, Cong Xue, Zhong‐Yu Yuan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | MedComm |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/mco2.70221 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer
by: Sarah Alexandrou, et al.
Published: (2025-08-01) -
Comparative long-term outcomes of first-line CDK4/6 inhibitors plus endocrine therapy versus endocrine therapy in patients with HR+/HER2-metastatic or advanced breast cancer: a meta-analysis
by: Xiaojian Wang, et al.
Published: (2025-07-01) -
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors
by: Roberta Scafetta, et al.
Published: (2025-08-01) -
PSMD12 promotes hepatocellular carcinoma progression by stabilizing CDK1
by: Xingyu Peng, et al.
Published: (2025-06-01) -
Optimizing Post-CDK4/6i Strategies In HR +/HER2− Advanced Breast Cancer: A Contemporary Evidence-Based Framework
by: Teena Rajan, et al.